Giulio Maria Pasinetti
Department of Psychiatry
Unitec Institute of Technology
Dr. Giulio Maria Pasinetti is a Professor of Psychiatry, Professor of Neuroscience and Professor of Geriatrics and Adult Development, in the Department of Psychiatry at Mount Sinai School of Medicine, New York. Dr. Pasinetti graduated from Milan University School of Medicine in 1982, and he received his Ph.D. from the University of Milan in 1988. He joined the Mount Sinai School of Medicine's faculty in 1996 and has consistently maintained an outstanding record of excellence and exceptional productivity. Dr. Pasinetti is a recipient of several academic awards including the prestigious Zenith and Temple awards from the Alzheimer's Association. Most recently, Dr. Pasinetti was awarded ''The Faculty Council Award'' for academic excellence at Mount Sinai School of Medicine and "The Charles Dana Alliance for Brain Research Award" from Dana Foundation, recognizing productivity and the worldwide leadership in his field of expertise, which further emphasizes his standing as an academic role model. Dr. Pasinetti was also recently awarded with an NIH funded research grant supporting a ''Center of Excellence for Research in Complementary and Alternative Medicine in Alzheimer's disease,'' of which he is the Principal Investigator and Director. Dr. Pasinetti also serves as the Director of the Basic and Biomedical Research and Training Program, GRECC James J. Peters Veterans Affairs Medical Center at the Bronx VA.
Pasinetti′s research into one of mankind’s most puzzling diseases has the potential to unlock one of the greatest mysteries of the human mind. His expertise in Alzheimer’s disease (AD) and the molecular mechanisms influencing clinical dementia’s onset and progression made one of the world’s most sought after leaders in this field. His research experience in neurodegenerative diseases offers unprecedented possibilities towards the discovery of novel strategies in the treatment of AD, as well as other diseases and conditions. Along with this line of study, the proposed research application seeks to investigate the therapeutic validity of delaying the onset and possibly slowing the progression of AD, dementia, and amyloid neuropathology